Journal Club: Spatial Niches Across Organs — How Cellular Geography Shapes Immunity, Repair, and Disease

· 11 min read · Paper Feed

Journal Club: Spatial Niches Across Organs — How Cellular Geography Shapes Immunity, Repair, and Disease

Conceptual illustration: Spatial Niches Across Organs — How Cellular Geography Shapes Immunity, Repair, and Disease

Introduction

For decades, molecular biology has been telling us what cells are doing. Bulk RNA-seq gave us averages; single-cell RNA-seq gave us a parts list of cell types and states. But in tissues, biology happens in neighborhoods: a macrophage needs to be next to a T cell to license its activation, a cardiomyocyte's fate depends on whether it sits in the infarct core or the border zone, and a microglial transcript is meaningless without knowing whether the cell touches a plaque or sits in quiescent white matter. Spatial transcriptomics (ST) is the toolset that finally lets us reconstruct those neighborhoods, measuring gene expression while preserving each cell's address in the tissue.

In this journal club, we dissect three papers that span the colon, heart, and brain but converge on a single idea: cellular identity is inseparable from cellular geography. Zhang et al. (2025, Cell Discovery) provide a mechanistic case study in metastatic colorectal cancer, identifying a C1QC⁺ resident tissue macrophage (RTM)–CD4⁺ T cell niche that predicts immunotherapy response. Hanna (2026, Frontiers in Cell and Developmental Biology) reviews how ST has reshaped our understanding of cardiac homeostasis and injury, organizing technologies from Visium to MERFISH. Cha et al. (2026, International Journal of Molecular Sciences) survey the same revolution in the aging and diseased brain, from Alzheimer's to glioblastoma. Together, they form a triptych showing how the same conceptual and computational frameworks can be deployed across organs to decode microenvironmental logic.

Paper 1: A C1QC⁺ Macrophage–CD4⁺ T Cell Niche Predicts Immunotherapy Response in Colorectal Cancer

Zhang et al., Cell Discovery (2025)

Key Findings

  • A discrete immune niche predicts response. Using a spatial immune atlas of 314,774 cells built from imaging mass cytometry (n=50), spatial proteomics (n=50), spatial transcriptomics (n=9), scRNA-seq, bulk RNA-seq, and bulk proteomics, the authors found that C1QC⁺ resident tissue macrophages are significantly more abundant in immunotherapy responders, regardless of microsatellite status (MSI or MSS).
  • Spatial proximity, not just presence, matters. C1QC⁺ RTMs co-localize with CD4⁺ T cells in responders, with MHC-II expression on C1QC⁺ macrophages facilitating their interaction and supporting a highly activated CD4⁺ T cell state.
  • Fibroblasts break the niche. In non-responders, cancer-associated fibroblasts physically disrupt C1QC⁺ RTM–CD4⁺ T cell interactions, offering a spatial explanation of immunotherapy resistance.
  • Whole-genome screening further nominated key antigen-presentation genes in C1QC⁺ RTMs, suggesting that their ability to engage CD4⁺ T cells is at least partly genetically programmed.

Methodology & Study Design

The authors deployed a spatial multi-omics pipeline rarely matched in scale: imaging mass cytometry for ~40-marker single-cell phenotyping on FFPE tissue, spatial proteomics (likely multiplexed IF/CODEX-style), and spatial transcriptomics for transcript-level validation. They anchored these to scRNA-seq for cell-type definition and used bulk RNA-seq + proteomics for cross-cohort validation. Whole-genome CRISPR-style screening was then layered on to nominate drivers of antigen presentation in C1QC⁺ macrophages. The integrative design is what enables the central claim: that niche topology, not just cellular composition, dictates response.

Significance

This paper challenges the long-standing assumption that tumor-associated macrophages are uniformly immunosuppressive. Instead, it positions C1QC⁺ macrophages as context-dependent anti-tumor allies whose benefit is contingent on forming a structured niche with CD4⁺ T cells. It also outperforms bulk metrics like overall T cell density as a predictor of response, suggesting that spatial biomarkers (e.g., distance between C1QC⁺ macrophages and CD4⁺ T cells in defined tissue regions) could enter clinical pipelines for both MSI and MSS CRC, the latter being a major unmet need given that MSS tumors comprise ~85% of CRC and respond poorly to checkpoint blockade.

Paper 2: Spatial Transcriptomics in Cardiac Homeostasis and Injury — A Technological and Conceptual Tour

Hanna, Frontiers in Cell and Developmental Biology (2026)

Key Findings

  • Methods matter, and there are now real choices. The review systematically categorizes ST platforms: sequencing-based methods (Visium, Stereo-seq) offer transcriptome-wide discovery at the cost of resolution, while imaging-based methods (MERFISH, Xenium, CosMx) provide subcellular resolution with high sensitivity for targeted gene panels.
  • The infarcted heart is not one tissue. ST has revealed distinct cell states, pathway activities, and cell–cell communication programs across infarct core, border zone, and remote myocardium, a zonation that bulk and scRNA-seq cannot resolve.
  • Next frontier: spatial multi-omics. Emerging methods such as sequential immunofluorescence (seq-IF) and expansion proteomics (iPEX) enable simultaneous profiling of transcriptome, proteome, and (potentially) chromatin accessibility from the same section.
  • Macrophages emerge as spatially heterogeneous actors across zones of injury and repair, echoing themes from the CRC paper but in a regenerative context.

Methodology & Study Design

As a review, Hanna's contribution is synthetic: it maps current technologies to current biological questions in cardiovascular biology. The methodological framework, platform-by-platform trade-offs (resolution, sensitivity, gene coverage, throughput), is the practical takeaway for any lab deciding whether to invest in Visium vs. Xenium, or how to integrate ST with existing scRNA-seq and scATAC-seq datasets.

Significance

Cardiovascular disease remains the world's leading cause of death, and many of its central processes (infarct healing, adverse remodeling, arrhythmogenic substrate formation) are fundamentally spatial. Hanna's review crystallizes how ST has shifted cardiac biology from a list of cell types to a map of neighborhoods, setting the stage for spatially targeted therapies (e.g., border-zone macrophage modulation, region-specific delivery).

Paper 3: Spatial Transcriptomics for the Aging and Diseased Brain

Cha et al., International Journal of Molecular Sciences (2026)

Key Findings

  • ST is essential for brain biology. The brain's laminar architecture, white-matter tracts, and lesion microenvironments make it a paradigm case for spatial methods; Cha et al. catalog both NGS-based (Visium, Stereo-seq, Slide-seq) and in situ (MERFISH, seqFISH+, Xenium) platforms for brain applications.
  • Aging has a spatial signature. Region- and cell-type-specific changes across the aging brain include altered neuronal and glial transcriptional programs in defined anatomical zones, patterns invisible to dissociated single-cell approaches.
  • Neurodegenerative lesions are spatially organized microenvironments. In Alzheimer's disease, the authors describe amyloid-plaque-associated and tau-associated niches with characteristic microglial and astrocytic states. In Parkinson's, similar logic applies to α-synuclein pathology. In glioblastoma, ST reveals spatially isolated tumor cell states and an immunosuppressive microenvironment that helps explain immunotherapy resistance, a notable parallel to the CRC findings.

Methodology & Study Design

Like Hanna's review, Cha et al. is a methods-and-applications synthesis, but focused on neurobiology. They explicitly compare platform principles (Visium's 55-µm spots vs. Stereo-seq's sub-micron bins vs. imaging-based subcellular resolution) and pair each with example brain studies. The review also catalogs brain-specific ST data resources, which is useful for labs planning to mine public atlases rather than generate new data.

Significance

Cha et al. make the case that ST is the essential tool for understanding the spatial logic of brain function and pathology, with explicit potential for precision medicine — for example, identifying peri-plaque microglial states as drug targets in AD or spatially resolved tumor subclones as therapeutic vulnerabilities in GBM. Their review underscores that where a cell sits in the brain is as informative as what it expresses.

Synthesis & Discussion

What the three papers share

All three converge on a central claim: cell identity and cell function are inseparable from cell location. They each show that the same conceptual axis — cellular heterogeneity × spatial context — drives immune activation in tumors (Zhang), injury and remodeling in the heart (Hanna), and degeneration or tumor biology in the brain (Cha). They also share methodological DNA: scRNA-seq for cell-type discovery, ST for spatial mapping, and an explicit move toward multi-modal integration (transcriptome + proteome + epigenome).

Tensions and contrasts

  • Discreteness vs. continuum. Zhang et al. identify a discrete, targetable niche (C1QC⁺–CD4⁺) with a clear binary signal (responder vs. non-responder). The cardiac and brain reviews emphasize continuous, multi-zone landscapes with overlapping gradients — a reminder that not every disease has a clean spatial biomarker.
  • Macrophages as friend or foe. In CRC, C1QC⁺ macrophages are anti-tumor allies in the right niche. In aging brain and injured heart, related myeloid states often correlate with chronic inflammation, fibrosis, or dysfunction. The same cell marker (e.g., C1QC, TREM2) can therefore have opposite meanings depending on context — an important caveat for any lab mining myeloid signatures across organs.
  • GBM vs. CRC parallel. Cha et al.'s description of immunosuppressive niches in glioblastoma is a striking mirror of Zhang et al.'s CRC findings: in both, spatial organization of myeloid and lymphoid cells shapes immunotherapy response, hinting at convergent principles of tumor immune evasion.

Emerging patterns

  • Macrophage/microglia-centered niches are a recurring axis of disease biology — anti-tumor in CRC (when properly engaged), reparative or pathological in heart and brain depending on zone and time.
  • The field is moving from "which cells?" to "which neighborhoods?" — border zones, peri-plaque hubs, fibroblast-disrupted macrophage–T cell gaps.
  • A growing methodological wave: imaging-based ST (MERFISH, Xenium, CosMx) and spatial multi-omics (seq-IF, iPEX, spatial ATAC) are pushing toward single-cell and even subcellular resolution.

Open questions

  • How generalizable is the C1QC⁺–CD4⁺ niche across tumors and organs? Universal predictor, or CRC-specific?
  • Can we causally engineer or disrupt these niches (e.g., via fibroblast reprogramming, myeloid education) to improve outcomes?
  • How do these niches evolve over time, across the course of immunotherapy, during infarct healing, or across the lifespan in the aging brain?
  • What standard analytical frameworks will let us compare spatial niches across organs and diseases rather than reinventing them per study?

For Your Lab Meeting

  1. Method choice: If your lab could afford only one spatial platform for a new project, would you choose Visium/Stereo-seq (whole-transcriptome, lower resolution) or Xenium/MERFISH (targeted panel, subcellular resolution)? What would drive that decision — gene panel breadth, resolution, or integration with existing scRNA-seq?
  2. Niche generalizability: The C1QC⁺–CD4⁺ niche predicts anti–PD-1 response in CRC. Would you expect the same niche to predict response to CAR-T or bispecific antibodies? What about in non-CRC tumors (e.g., pancreatic, ovarian)?
  3. Myeloid duality: C1QC⁺ macrophages appear pro-immune in CRC but disease-associated microglial states appear deleterious in Alzheimer's. How would you experimentally decouple context from cell-intrinsic program to test whether the same cell can be both?
  4. Spatial biomarkers vs. bulk signatures: Zhang et al. show that spatial proximity outperforms T cell density alone. Should clinical biomarker pipelines shift toward spatially resolved assays (e.g., multiplex IF) over bulk RNA-seq-based signatures, and what are the practical barriers (cost, standardization, regulatory)?
  5. Multi-omics integration: Both reviews emphasize the need for spatial transcriptome + proteome + epigenome integration. What computational frameworks (e.g., Seurat v5, MOFA+, Tangram, Cell2location) are best suited for cross-modal niche identification, and where do they fall short?

Key Terms

  • Spatial transcriptomics (ST): A family of technologies that measure gene expression in intact tissue while preserving spatial coordinates. Includes sequencing-based platforms (Visium, Stereo-seq, Slide-seq) and imaging-based platforms (MERFISH, Xenium, CosMx).
  • C1QC⁺ resident tissue macrophage (RTM): A tissue-resident macrophage subset marked by expression of C1QC (a complement component), often associated with antigen presentation via MHC-II and, in some contexts, anti-tumor immunity.
  • Imaging mass cytometry (IMC): A multiplexed imaging method that uses metal-tagged antibodies and mass spectrometry to quantify ~40 markers simultaneously at subcellular resolution on FFPE tissue.
  • Spatial niche / neighborhood: A spatially restricted cluster of interacting cell types whose composition and proximity (rather than mere presence) defines a functional unit of tissue biology — e.g., the C1QC⁺–CD4⁺ niche, the cardiac border zone, the peri-plaque microenvironment.
  • scRNA-seq: Single-cell RNA sequencing, a dissociated-cell technology that provides high-resolution transcriptomes of individual cells but loses all spatial information — the complement to ST.

References

  1. Hangyu Zhang, Libing Hong, Zhen Dong, Shan Xin, Bo Lin, Jinlin Cheng, et al. (2025). Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response. Cell Discovery. https://doi.org/10.1038/s41421-025-00811-2

  2. Hanna A (2026). Decoding cardiac homeostasis and injury: the evolving landscape of spatial transcriptomics.. Frontiers in cell and developmental biology. https://doi.org/10.3389/fcell.2026.1772507

  3. Cha S, Kim J, Kim J, Kim D, Song H, Lim KS, et al. (2026). Spatial Transcriptomics for Dissecting Cellular and Molecular Heterogeneity in the Aging and Diseased Brain.. International journal of molecular sciences. https://doi.org/10.3390/ijms27146149

Spatial Transcriptomics Spatial Omics Single-Cell